NCT00019396 2024-03-04
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
19 trialsNCT00020475 2024-03-04
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02320305 2020-01-14
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT00074230 2015-05-12
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
University Hospital Erlangen
Phase 1/2 Completed
NCT00091338 2015-04-30
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00089063 2015-04-15
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025181 2014-05-22
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
University of Southern California
Phase 1 Completed
NCT00031733 2014-05-22
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Phase 2 Completed
NCT00334776 2014-05-21
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Southern California
Phase 2 Completed
NCT00002952 2013-09-05
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
University of Chicago
Phase 1/2 Completed
NCT00003792 2013-06-26
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00019214 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00019721 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019994 2013-06-19
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006385 2011-11-08
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00001685 2008-03-04
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00559026 2007-11-16
DTIC-melvacc
Istituto Superiore di SanitÃ
Phase 1 Completed